JAK2 Mutation

CI-VAR-00002826Explore in graph →CIViC 5039

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
MSI High AND ( B2M Mutation OR JAK1 Mutation OR JAK2 Mutation )	Anti-PD1 Monoclonal Antibody	Predictive	B	Supports Sensitivity Response	2	submitted	EID12150 Thirty-five MSI-H/dMMR patients were treated with anti-PD-1 therapy. Of the 35 patients, 10 patients harboured B2M mutations, and 8 patients harboured JAK mutations. A low TMB score was noted in patie… (full text at CIViC) PMID 35343934 · Zhang et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.